An overview of the evidence and mechanisms of herb–drug interactions

Pius S. Fasinu1, Patrick J. Bouic2,3 and Bernd Rosenkranz1*

1 Division of Pharmacology, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa
2 Division of Medical Microbiology, Faculty of Health Sciences, University of Stellenbosch, Cape Town, South Africa
3 Synexa Life Sciences, Montague Gardens, Cape Town, South Africa

INTRODUCTION

There is increasing consumptions of medicinal herbs and herbal products globally, cutting across social and racial classes, as it is observed both in developing and developed countries (Cheng et al., 2002; Bodeker, 2007; Mitra, 2007). Medicinal plants were the major agents for primary health care for many centuries before the advent of modern medicine (Sheeja et al., 2006). Their use however declined in most developed western countries during the last century’s industrialization and urbanization (Ogbonnia et al., 2008). In the past two decades however a new resurgence in medicinal plants consumption was observed. According to the WHO, about 70% of the world population currently uses medicinal herbs as complementary or alternative medicine (Wills et al., 2000). It is estimated that over 40% of the adult American population consume herbal products for one medical reason or the other (Tachjian et al., 2010). A recent study involving 2055 patients in the US also reveals that the consumption pattern of traditional medications has no significant gender or social difference (Kessler et al., 2001). Consumption rate has also been particularly exponential in Canada (Calixto, 2000), Australia (Bensoussan et al., 2004), as well as Europe where the highest sales of herbal products have been reported in Germany and France (Capasso et al., 2003). In Africa, there is continuous addition to the list of medicinal herbs while consumption rate is also increasing. Between 60 and 85% native Africans use herbal medicine usually in combination (Van Wyk et al., 2009).

The indications for herbal remedies are diverse as they are employed in the treatment of a wide range of diseases (Ernst, 2005). Studies have shown that 67% of women use herbs for perimenopausal symptoms, 45% use it in pregnancy, and more than 45% parents give herbal medications to their children for various medical conditions (Ernst, 2004). Regulations in most countries do not require the demonstration of therapeutic efficacy, safety, or quality on the part of herbal remedies as most of them are promoted as natural and harmless (Homsy et al., 2004; Routledge, 2008). It is pertinent however, that herbs are not free from side effects as some have been shown to be toxic (Déciga-Campos et al., 2007; Patel et al., 2011). Recent study has shown...
habitual pattern of concomitant consumption of herbal and prescription medication. Kaufman et al. (2002) reported that 14–16% of American adult population consume herbal supplements often concomitantly with prescribed medications. Also, 49.4% of Israeli consumers of herbal remedies use them with prescription drugs (Giveon et al., 2004). This is significant bearing in mind that less than 40% of patients disclose their herbal supplement usage to their health care providers coupled with the fact that many physicians are unaware of the potential risks of herb–drug interactions (HDI; Klepser et al., 2000).

HDI is one of the most important clinical concerns in the concomitant consumption of herbs and prescription drugs. The necessity of polypharmacy in the management of most diseases further increases the risk of HDI in patients. The ability of intestinal and hepatic CYP to metabolize numerous structurally unrelated compounds, apart from being responsible for the poor oral bioavailability of numerous drugs is responsible for the large number of documented drug–drug and drug–food interactions (Quintieri et al., 2008). This is more so, considering that oral drug delivery is the most employed in the management of most disease conditions in which case, drug interaction alters both bioavailability and pharmacokinetic disposition of the drug. This alteration and the resulting poor control of plasma drug concentrations would particularly be of concern for drugs that have a narrow therapeutic window or a precipitous dose–effect profile (Aungst, 2000; Perucca, 2006). The risk of pharmacokinetic drug interaction poses two major extremity challenges – pharmacotoxicity and treatment failure. The former can result from the inhibition of the metabolic enzymes responsible for the metabolism and clearance of the drugs while the latter may be the consequence of enzymatic induction leading to faster drug metabolism. This is in addition to the intrinsic pharmacodynamic actions of the herbal products themselves which may include potentiating, additive, antagonism, or neutralization effects.

Until recently, HDI was often unsuspected by physicians for several reasons. Most trained physicians lack adequate knowledge on herbal drugs and their potentials for drug interactions (Clement et al., 2005; Ozcakir et al., 2007; Fakeye and Onyemadu, 2008); herbal products also vary considerably in compositions depending on the source and package (Liang et al., 2004; Sousa et al., 2011); most patients do not consider it necessary to disclose their herbal consumptions to physicians who themselves hardly inquire such (Cassidy, 2003; Howell et al., 2006; Chao et al., 2008; Kennedy et al., 2008). Further challenges with herbal medications include scientific misidentification, product contamination and adulteration, mislabeling, active ingredient instability, variability in collection procedures, and failure of disclosure on the part of patients (Boulata and Nace, 2000). A fairly recent systematic review by Izzo and Ernst (2009) on the interactions between medicinal herbs and prescribed medications provide some more details on these.

Herbal products are made of complex mixture of pharmacologically active phytochemicals (Mok and Chau, 2006), most of which are secondary metabolites generated through the shikimate, acetate–malonate, and acetate–mevalonate pathways. These constituents include phenolics (such as tannins, lignins, quinolones, and salicylates), phenolic glycosides (such as flavonoids, cyanogens, and glucosinolates), terpenoids (such as sesquiterpenes, steroids, carotenoids, saponins, and iridoids), alkaloids, peptides, polysaccharides (such as gums and mucilages), resins, and essential oils which often contain some of the aforementioned classes of phytochemicals (Wills et al., 2000; Wang et al., 2008). This complexity increases the risk of clinical drug interactions.

**AIM, SEARCH STRATEGY, AND SELECTION CRITERIA**

The current review was therefore aimed at providing an overview of known and recently reported HDI with interest in the evidence available and the mechanism thereof. The review was systematically conducted by searching the databases of MEDLINE, PUBMED, EMBASE, and COCHRAINE libraries for original researches, and case reports on HDI using the following search terms or combinations thereof: “drug–herb,” “herb–drug,” “interaction,” “cytochrome P450,” “plant,” “extract,” “medicinal,” “concomitant administration,” “herbal and orthodox medicines.” Relevant search terms were employed to accommodate the various individual medicinal herbs employed in Africa, America, Asia, Europe, and Australia. The reported interactions and their mechanisms, with orthodox medications were searched and collated. Searches were not limited by date or place of publications but to publications available in English language.

**RESULTS CLINICAL PRESENTATION OF HERB–DRUG INTERACTIONS**

Clinical presentations of HDI vary widely depending on the herbs and the drugs concerned. Typical clinical presentation of HDI include the potentiation of the effects of oral corticosteroids in the presence of liquorice (Glycyrrhiza glabra; Liao et al., 2010); potentiation of warfarin effects with resultant bleeding in the presence of garlic (Allium sativum; Borrelli et al., 2007), dong quai (Angelica sinensis; Nutescu et al., 2006), or danshen (Salvia miltiorrhiza; Chan, 2001); decreased blood levels of nevirapine, amitriptyline, nifedipine, statins, digoxin, theophylline, cyclosporine, midazolam, and steroids in patients concurrently consuming St John’s wort (SIW; Hypericum perforatum; De Maat et al., 2001; Hendersen et al., 2002; Johne et al., 2002; Mannel, 2004; Borrelli and Izzo, 2009), decreased oral bioavailability of prednisolone in the presence of the Chinese herbal product xiao-chai-hu tang (shousaiko-to; Fugh-Berman, 2000); ginseng (Panax ginseng)-induced mania in patients on antidepressants (Engelberg et al., 2001); production of extrapyramidal effects as a result of the combination of neuroleptic drugs with betel nut (Areca catechu; Huang et al., 2003; Coppola and Mondola, 2012); increased blood pressure induced by tricyclic antidepressant-yohimbe (Pausinystalia yohimbe) combination (Tam et al., 2001), increased phenytoin clearance and frequent seizures when combined with Ayurvedic syrup shankhapushpi (Patsalos and Perucca, 2003), among other clinical manifestations. These clinical presentations depend on the mechanism of HDI.

**EVIDENCE-BASED HDI STUDIES AND CLINICAL RELEVANCE**

Herb–drug interactions have been reported through various study techniques. While these reports usually give evidence of potential interactions, the level of evidence varies often failing to predict the magnitude or clinical significance of such HDI. Apart from
the specific limitations attributable to study methods employed, major draw-back in deducing relevant conclusions from reported HDI include misidentification and poor characterization of specimen, presence and nature of adulterants (some of which may be allergens), variations in study methodologies including extraction procedures, source location of herbs involved, seasonal variation in the phytochemical composition of herbal materials, under-reporting and genetic factors involved in drug absorption, metabolism, and dynamics. Table 1 provides some limitations of the study methods.

Recently, structured assessment procedures are emerging in an attempt to provide levels of evidence for drug interactions. In addition to evidence of interaction, such assessment take into consideration clinical relevance of the potential adverse event resulting from the interaction, the modification- and patient-specific risk factors, and disease conditions for which the interaction is important. Van Roon et al. (2005) developed a system of hierarchical factors, and disease conditions for which the interaction is important. This can be applicable to HDI. This method particularly allows the extraction of HDIs that have been well established and those that are merely inferred from certain phytochemical characteristics. A modified form of this method as presented in Table 2 is applied in this paper to provide the nature and level of evidence for the HDIs mentioned.

**MECHANISMS OF HERB–DRUG INTERACTIONS**

The overlapping substrate specificity in the biotransformational pathways of the physiologic systems is seen as the major reason for drug–drug, food–drug, and HDI (Marchetti et al., 2007). The ability of different chemical moieties to interact with receptor sites and alter physiological environment can explain pharmacodynamic drug interactions while pharmacokinetic interactions arise from altered absorption, interference in distribution pattern as well as changes and competition in the metabolic and excretory pathways (Izzo, 2005). The major underlying mechanism of pharmacokinetic HDI, like drug–drug interaction, is either the induction or inhibition of intestinal and hepatic metabolic enzymes particularly the CYP enzyme family. Additionally, similar effect on drug transporters and efflux proteins particularly the p-glycoproteins in the intestines is responsible in most other cases (Meijerman et al., 2006; Nowack, 2008; Farkas et al., 2010). The pre-systemic activity of CYP and efflux proteins often influence oral bioavailability, thus the modulating activity of co-administered herbal products has been shown to result in pronounced reduction or increase in the blood levels of the affected drugs (Brown et al., 2008).

Potential for in vivo drug interactions are often inferred from in vitro studies with liver enzymes. The correlation of in vitro results with in vivo behavior has yielded reliable results in certain cases in terms of in vivo predictability although the extent of clinical significant is poorly inferable (Rostami-Hodjegan and Tucker, 2007; Iwamoto et al., 2008; Xu et al., 2009; Umehara and Camenisch, 2011). Thus most of the well established HDIs, as will be seen in subsequent sections, were initially demonstrated through in vitro studies.

The interaction of herbal products with hepatic enzymes can also result in pharmacodynamic effects (van den Bout-van den Beukel et al., 2008; Nivitabishekam et al., 2009; Asdaq and Inamdar, 2010; Dasgupta et al., 2010; Kim et al., 2010a.) Specific liver injury inducible by phytochemical agents includes elevation in transaminases (Zhu et al., 2004; Saleem et al., 2010), acute and chronic hepatitis (Stedman, 2002; Pierard et al., 2009), liver failure (Durazo et al., 2004), veno-occlusive disorders (DeLeve et al., 2002), liver cirrhosis (Lewis et al., 2006), fibrosis (Chitturi and Farrell, 2000), cholestasis (Chitturi and Farrell, 2008), zonal or diffusive hepatic necrosis (Savvidou et al., 2007), and steatosis (Wang et al., 2009). Mechanism of liver injury may include bioactivation of CYP, oxidative stress, mitochondrial injury, and apoptosis (Cullen, 2005).

### Table 1 | Comparison of study methods available for HDI.

| Report/study method | Comments | Advantages | Limitations to clinical inferences |
|---------------------|----------|------------|-----------------------------------|
| **In vitro studies**| Deliberate investigations employing metabolic enzymes, tissues, or organs, e.g., CYP-transfected cell lines, hepatic subcellular fractions, liver slices, intestinal tissues | Provide information on potential HDI, easy to perform, good for high throughput screenings; Compared to in vivo animal studies, results are closer to human if human liver-based technologies are employed | Variations in experimental vs clinical concentrations; other in vivo phenomena like protein binding and bioavailability are not accounted for; poor reproducibility of results; poor correlation to clinical situation |
| **In vivo studies**| Involves metabolic studies in mammals | Concentration and bioavailability of active components are taken into consideration | Results are often difficult to interpret due to species variation; use of disproportionate and non-physiologic dosages |
| **Case reports** | Patients diagnosed after history taking, from HDI | Ideal in providing information on HDI | Hardly discovered by physicians; infrequent with poor statistical values in relation to each medicinal herbs; under-reporting |
| **Human studies** | Involves the use of human subjects | The ideal study, providing directly extrapolative data on interactions | Expensive; too stringent ethical considerations; most subjects are healthy leaving out the effects of pathologies on drug metabolism; genetic variation in enzyme activity; poor representative population |
Table 2 | Quality of HDI evidence for clinical risk assessment.

| Level | Description of evidence |
|-------|--------------------------|
| 1     | Published theoretical proof or expert opinion on the possibility of HDI due to certain factors including the presence of known interacting phytochemicals in the herbs, structure activity relationship |
| 2     | Pharmacodynamic and/or pharmacokinetic animal studies; in vitro studies with a limited predictive value for human in vivo situation |
| 3     | Well documented, published case reports with the absence of other explaining factors |
| 4     | Controlled, published interaction studies in patients or healthy volunteers with surrogate or clinically relevant endpoint |

Induction and inhibition of metabolic enzymes

The CYP superfamily is generally involved in oxidative, peroxidative, and reductive biotransformation of xenobiotics and endogenous compounds (Nebert and Russell, 2002; Hiratsuka, 2011). It is conventionally divided into families and subfamilies based on nucleotide sequence homology (Fasinu et al., 2012). There is a high degree of substrate specificity among the various families. CYP belonging to the families 1, 2, and 3 are principally involved in xenobiotic metabolism while others play a major role in the formation and elimination of endogenous compounds such as hormones, bile acids, and fatty acids (Norlin and Wikvall, 2007; Amacher, 2010). The most important CYP subfamilies responsible for drug metabolism in humans are 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4, and 3A5 (Ono et al., 1996; Wang and Chou, 2010).

CYP1A1 and 1A2 are the two major members of the human CYP1A subfamily. CYP 1A1 is mainly expressed in extra-hepatic tissues such as the kidney, the intestines, and the lungs while CYP1A2 constitutes about 15% of total hepatic CYP (Martignoni et al., 2006). CYP2B6 is involved in drug metabolism while most other members of the CYP2B subfamily play less significant metabolic roles (Pavek and Dvorak, 2008). The subfamily 2C is the second most abundant CYP after 3A representing over 20% of the total CYP present in the human liver. It comprises three active members: 2C8, 2C9, and 2C19 all of which are also involved in the metabolism of some endogenous compounds including retinol and retinoic acid (Lewis, 2004). Few clinically relevant drugs including paracetamol, chloroxazalone, and enfurane are metabolized by CYP2E1, the most active of the 2E subfamily (Leclercq et al., 2000). CYP3A subfamily constitutes over 40% of the total CYP in the human body (although the levels may vary 40-fold among individuals) with CYP3A4 being the most abundant of all isoforms highly expressed in the liver and the intestines and participates in the metabolism of about half of drugs in use today (Ferguson and Tyndale, 2011; Singh et al., 2011). The specificity and selectivity of substrates and inhibitors for these enzymes are particularly useful in pharmacokinetic and toxicological studies.

Induction is the increase in intestinal and hepatic enzyme activity as a result of increased mRNA transcription leading to protein levels higher than normal physiologic values. When this happens, there is a corresponding increase in the rate of drug metabolism affecting both the oral bioavailability and the systemic disposition. In the formulation and dosage design of oral medications, allowance is often made for pre-systemic metabolism in order to achieve predictable systemic bioavailability. A disruption in this balance can result in significant changes in blood concentrations of the drugs. Certain herbal products have been shown to be capable of inducing CYP. Concomitant administration of enzyme-inducing herbal products and prescription drugs can therefore result in sub-therapeutic plasma levels of the latter with therapeutic failure as a possible clinical consequence.

Apart from enzyme induction, herbal products can also inhibit enzyme activities. The inhibition of CYP and other metabolic enzymes is usually competitive with instantaneous and inhibitor concentration-dependent effects (Zhang and Wong, 2005). Most inhibitors are also substrates of CYP (Zhou, 2008). This phenomenon alters pharmacokinetic profiles of xenobiotics significantly. As a result of the suppression of the anticipated pre-systemic intestinal and hepatic metabolism, unusually high plasma levels of xenobiotics are observed. Toxic manifestation could be the ultimate effect of this observation. An equally clinically important consequence of enzyme inhibition is drug accumulation due to subdued hepatic clearance. These effects will be of particular concern in drugs with narrow therapeutic window or steep dose–response profiles.

St John’s wort is one of the most widely used herbal antidepressants (Lawvere and Mahoney, 2005; Hoyland, 2011). It is a potent inducer of CYP3A4 and depending on the dose, duration and route of administration, it may induce or inhibit other CYP isozymes and P-gp (Roby et al., 2000; Markowitz et al., 2003b; Tannergren et al., 2004; Madabushi et al., 2006). Studies from case reports indicate that, due to its inducing effects on CYP3A4, it significantly reduces the plasma levels of CYP3A4 substrates including cyclosporine, simvastatin, indinavir, warfarin, amitriptyline, tacrolimus, oxycodone, and nevirapine (Henderson et al., 2002; Johne et al., 2002; Nieminen et al., 2010; Vlachoiannis et al., 2011). It has also been reported that the alteration in the blood serum concentration of cyclosporine due to SJW has led to organ rejection in patients (Ernst, 2002; Murakami et al., 2006). Reports of breakthrough bleeding and unplanned pregnancies due to interaction between SJW and oral contraceptives have also been documented (Hu et al., 2005). The group of drugs with the highest potential for clinically significant pharmacokinetic drug interaction with SJW is the antidepressants as SJW itself is consumed by patients with depression. Its concomitant use with SR1 like sertraline and paroxetine has been reported to result in symptoms of central serotonergic syndrome (Barbenel et al., 2000; Dannawi, 2002; Spinella and Eaton, 2002; Birmes et al., 2003; Bonetto et al., 2007). It has also been said to increase the incidence of hypoglycemia in patients on tolbutamide without apparent alteration in the pharmacokinetic profile of tolbutamide (Mannel, 2004). It also inhibits the production of SN-38, an active metabolite of irinotecan, in cancer patients.
Amitriptyline is a substrate to both CYP3A4 and intestinal P-gp. The risk of therapeutic failure is thus high due to induction of CYP3A4-dependent metabolism activities resulting in poor oral bioavailability. In a study by John et al. (2002), a 21% decrease in the area under the plasma concentration–time curve of amitriptyline was observed in 12 depressed patients who were concomitantly administered with extracts of SJW and amitriptyline for 2 weeks.

Other CYP and P-gp substrates whose pharmacokinetic profile have been reportedly altered by SJW include anticoagulants like phenprocoumon and warfarin; antiarrhythmias like fexofenadine; antiretroviral drugs including protease inhibitors and reverse transcriptase inhibitors; hypoglycemic agents such as tolbutamide; immunosuppressants like cyclosporine, tacrolimus, and mycophenolic acid; anti-inflammatory agents such as carbamazepine; anti-cancer like irinotecan; bronchodilators like theophylline; antitussive like dextromethorphan; cardiovascular drugs like statins, digoxin, and dihydropyridine calcium channel blockers; oral contraceptives; opiates like methadone and loperamide; and benzodiazepines including alprazolam and midazolam (Greeson et al., 2001; Di et al., 2008; Hojo et al., 2011). Following a single dose administration of 300 mg standardized extracts of SJW containing 5% hyperforin in humans, a maximum plasma concentration of 0.17–0.5 μM hyperforin yielding a $[I/K_c]>0.22$, in vivo extrapolation suggests a high possibility of in vivo pharmacokinetic drug interaction (Agrosi et al., 2000). Bray et al. (2002) confirmed through animal studies that SJW modulates various CYP enzymes. Dresser et al. (2007) demonstrated that SJW is capable of inducing CYP3A4 in healthy subjects through the observation of increased urinary clearance of midazolam. Thus animal and human studies further confirm SJW as containing both inhibitory and inducing constituents on various CYP isozymes. These effects may depend on dosage and duration of administration, and may also be species- and tissue-specific. While the individual phytochemical constituents of SJW have elicited varying effects on the metabolic activity of the CYP isozymes, whole extracts and major constituents especially hyperforin have been reported to inhibit the metabolic activities of CYP1A2, 2C9, 2C19, 2D6, and 3A4 via in vitro studies and in vivo studies (Lee et al., 2006; Madabushi et al., 2006; Hokkanen et al., 2011).

Ginkgo biloba have been reported to induce CYP 2C19-dependent omeprazole metabolism in healthy human subjects (Yin et al., 2004). Piscitelli et al. (2002) in a garlic–saquinavir interaction study reported 51% decrease in saquinavir oral bioavailability caused by the presence of garlic and attributable to garlic-induced CYP3A4 induction. Its effects on the warfarin pharmacokinetic has also been reported in animal models (Taki et al., 2012).

Although grapefruit juice is not consumed for medicinal purposes, the discovery of the inhibitory activity of its flavonoid contents on CYP has led to further researches in medicinal herbs which have revealed HDI potentials in flavonoid-containing herbal remedies (Choi and Burm, 2006; Palombo, 2006; Paine et al., 2008; Quintieri et al., 2008; Alvarez et al., 2010). A related CYP inhibitor is rotenone. By interfering with the electron transfer of the heme iron, rotenone, a naturally occurring phytochemical found in several plants such as the jicama vine plant is known to inhibit CYP activity (Sanderson et al., 2004). Resveratrol, a natural polymer, and tryptophan, an amino acid have been documented as potent CYP inhibitors (Rannug et al., 2006). Some herbal medications and their phytochemical constituents capable of interacting with CYP are presented in Table 3. A more detailed involvement of CYP in HDI is detailed in some recently published reviews (Delgoda and Westlake, 2004; Pal and Mitra, 2006; Cordia and Steenkamp, 2011; Liu et al., 2011).

Phase II metabolic enzymes including uridine diphosphoglucuronosyl transferase (UGT), N-acetyl transferase (NAT), glutathione S-transferase (GST), and sulfo transferase (ST) catalyze the attachment of polar and ionizable groups to phase I metabolites aiding their elimination. While cytochrome P450-mediated HDI have been extensively investigated in various studies, the effects of herbal extracts on phase II enzymes have not been adequately studied. However, there is sufficient evidence in literature to suggest the potentials of phase II enzymes to induce clinically significant HDI.

In a study carried out in rat models by Sheweita et al. (2002), extracts of hypoglycemic herbs, Cymbopogon proximus, Zygophyllum coccineum, and Lupinus albus reduced the activity of GST and GSH. Curcumin, from Curcuma longa, an herbal antioxidant with anti-inflammatory and antitumor properties increased the activity of GST and quinone reductase in the ddY mice liver (Iqbal et al., 2003). Valerian, an herbal sleeping aid has also demonstrated the potential of inducing HDI through the inhibition of UGT. Up to 87% of inhibition of UGT activity by valerian extract was reported in an in vitro study utilizing estradiol and morphine as probe substrate (Alkhary and Frye, 2007). Kampo, a traditional Japanese medicine made of a mixture of several medicinal herbs has shown inhibitory effects on some phase II enzymes. In an in vitro study by Nakagawa et al. (2009), nine out of 51 components of kampo medicine elicited more than 50% inhibition of UGT2B7-mediated morphine 3-glucuronidation. In the same study, extracts of kanzo (Glycyrrhiza radix), daio (Rhei rhizoma), and keihi (Cinnamomi cortex) elicited more than 80% inhibition of morphine AZT glucuronidation. This result agrees with Katoh et al. (2009) who carried out similar studies on rhei, keihi, and ogoron (Scutellariae radix).

Apart from the well-known effects on Ginkgo biloba on CYP enzymes as illustrated earlier, its extracts have demonstrated potent inhibition of mycophenolic acid glucuronidation investigated in human liver and intestinal microsomes (Mohamed and Frye, 2010).

In a study to investigate the influence of 18 herbal remedies on the activity of human recombinant sulfotransferase 1A3 employing dopamine and ritodrine as substrates, extracts of grape seed, milk thistle, gymnema, SJW, ginkgo leaf, banana, rafuma, and peanut seed coat showed potent inhibition with IC50 values lower than putative gastrointestinal concentration (Nagai et al., 2009). Similarly, Mohamed and Frye (2011b) reported the inhibition of UGT1A4 by green tea derived epigallocatechin gallate; UGT 1A6 and UGT1A9 by milk thistle; UGT 1A6 by saw palmetto; and UGT 1A9 by cranberry. A recent publication presents evidence of potential HDI mediated by UGT (Mohamed and Frye, 2011a).

Certain phytochemicals including coumarin, limettin, auraptene, angelicin, bergamottin, imperialin, and isopimpinellin have also been reported to be capable of inducing...
Table 3 | Some herbal products known to interact with CYP and efflux proteins.

| Medicinal Plant and parts used | Scientific name | Major constituents | Mechanism of drug interactions | Candidates for interactions | LE | Reference |
|-------------------------------|-----------------|--------------------|-------------------------------|-----------------------------|----|-----------|
| Cranberry (fruit extract)     | *Vaccinium macrocarpon* | Anthocyanins, flavonoids | Inhibition of CYP enzymes and P-gp | Warfarin, CYP1A2, 2C9, and 3A4 substrates | 4 | Li et al. (2009), Kim et al. (2010b), Roberts and Flanagan (2011), Hamann et al. (2011) |
| Dong quai (root)              | *Angelica sinensis* | Flavonoids, coumarins | Inhibition of CYP1A2, 3A4, and P-gp | CYP substrates | 3 | Scott and Elmer (2002), Tang et al. (2006), Sevior et al. (2010) |
| Gan cao (root)                | *Glycyrrhiza uralensis* | Glycyrrhizin | CYP2C9 and 3A4 induction | Warfarin, Lidocaine, CYP2C9, and 3A4 substrates | 2 | Mu et al. (2006), Tang et al. (2009) |
| Garlic (bulb)                 | *Allium sativum* | Allicin, phytoncide | CYP 3A4 and P-gp induction | Saquinavir, warfarin, CYP2D6, and 3A4 substrates | 4 | Markowitz et al. (2003a), Cox et al. (2008), Berginc and Kristl (2012) |
| Germander (leaves)            | *Teucrium chamaedrys* | Saponins, flavonoids, diterpenoids | Production of toxic CYP3A4-induced metabolites | CYP3A4 inducers like Phenobarbital, rifampicin | 3 | De Berardinis et al. (2000), Savvidou et al. (2007) |
| Ginseng (root)                | *Panax ginseng* | Ginsenosides | Inhibition and induction of CYP2C9, 2C19, 2D6, and 3A4 activity | Imatinib, CYP2E1, and 2D6 substrates | 4 | Gurley et al. (2005a), Bilgi et al. (2010), Malati et al. (2011) |
| Grape seed (seed oil)         | *Vitis vinifera* | Proanthocyanidin, resveratrol | Decreased CYP2C19, 2D6, and 3A4 activity | CYP2C19, 2D6, and 3A4 substrates | 4 | Nishikawa et al. (2004) |
| Kava kava (root)              | *Piper methysticum* | Kavainactones | Decreased CYP1A2, 2D6, 2E1, and 3A4 activity | CYP substrates | 4 | Gurley et al. (2005b), Teschke (2010), Sarris et al. (2011) |
| Liquorice (root)              | *Glycyrrhiza glabra* | Inhalant | Inhibition of CYP2B6, 2C9 and 3A4 | CYP2B6, 2C9 and 3A4 substrates | 4 | Kent et al. (2002), Al-Deeb et al. (2010), Methlie et al. (2011) |
| St John’s wort (aerial parts) | *Hypericum perforatum* | Hyperforin, hypericin, flavonoids | Inhibition and induction of CYP and P-gp | Orally administered CYP substrates | 4 | Hu et al. (2005), Hafner et al. (2009), Lau et al. (2011) |

LE, level of evidence.
hepatic GST activities (Kleiner et al., 2008). While the clinical significance of these findings are yet to be determined, it is noteworthy that phase II metabolic enzymes may play significant roles in HDIs.

**Inhibition and induction of transport and efflux proteins**

The ATP-binding cassette (ABC) family of drug transporters plays significant roles in the absorption, distribution, and elimination of drugs. P-gp, the most studied member of this family is a 170-kDa plasma glycoprotein encoded by the human MDRI gene. It is constitutively expressed in a number of body tissues and concentrated on the apical epithelial surfaces of the bile canaliculi of the liver, the proximal tubules of the kidneys, the pancreatic ductal cells, the columnar mucosal cells of the small intestine, colon, and the adrenal glands (Marzolini et al., 2004; Degorter et al., 2012). It is actively involved in drug absorption and elimination from the intestines the liver, kidneys, and the brain. Specifically these proteins are involved in the processes of hepatobiliary, direct intestinal, and urinary excretion of drugs and their metabolites (Szakács et al., 2008). Thus, the modulation of P-gp, or competitive affinity as substrates for its binding sites by co-administered herbs presents a potential for alteration in the pharmacokinetic profile of the drug.

Pharmacokinetic interaction occurs when herbal drugs inhibit or decrease the normal activity level of drug transporters through a competitive or non-competitive mechanism. Interactions can also occur through the induction of transport proteins via the increase of the mRNA of the relevant protein. Studies have identified a number of clinically important P-gp inhibitors including phytochemicals – flavonoids, furanocoumarins, reserpine, quindine, yohimbine, vincristine, vinblastine among others (Krishna and Mayer, 2001; Zhou et al., 2004; Patanasethanont et al., 2007; Iwanaga et al., 2010; Eichhorn and Efferth, 2011; Yu et al., 2011).

Borrel et al. (1994) reported that mobile ionophores such as valinomycin, nonactin, nigericin, monensin, calcimycin, and lasalocid inhibit the efflux of anthracycline by P-gp whereas channel-forming ionophores such as gramicidin do not (Larsen et al., 2000). A number of herbal products which interact with CYP also have similar effects on transport proteins (Table 3). The transport proteins are actively involved in the pharmacokinetics of anti-cancer drugs and account for one of the well-known mechanisms of multiple resistance of cancerous cells to chemotherapeutic agents (Bebawy and Sze, 2008; Bosch, 2008; He et al., 2011). The influence of some herbs on transport proteins is presented in Table 4. Clinically relevant interactions between herbal medicine and chemotherapeutic agents are detailed in a recent review by Yap et al. (2010).

**Alteration of gastrointestinal functions**

Besides their influence on the intestinal metabolic enzymes and efflux proteins, herbal medications can alter the absorption of concomitantly administered medicines through a number of mechanisms. Changes in the gastrointestinal pH and other biochemical factors can alter dissolution properties and the absorption of pH-dependent drugs such as ketoconazole and itraconazole. Complexation and chelation, leading to the formation of insoluble complexes and competition at the sites of absorption especially with site-specific formulations can greatly affect the absorption of medicines. Anthranoid-containing plants – cassia (Cassia senna), Cascara (Rhamnus purshiana), rhubarb (Rheum officinale), and soluble fibers including guar gum and psyllium can decrease drug absorption by decreasing GI transit time. They are known to increase GIT motility. On concomitant use with prescribed medication, significant alteration in the absorption of the latter has been reported due to decreased GI transit time (Fugh-Berman, 2000).

**Table 4 | Influence of herbal products on transport proteins.**

| Drug transporter | Anti-cancer substrates | Interacting herbal products | LE  | Reference |
|-----------------|------------------------|-----------------------------|-----|-----------|
| P-glycoprotein  | Actinomycin D, daunorubicin, doxorubicin, etoposide, irinotecan, mitoxantrone, paclitaxel, teniposide, topotecan, vinblastine, vincristine, tamoxifen, mitomycin C, tipifarnib, epirubicin, bisantrene | Rosmarinus officinalis       | 2   | Oluwatuyi et al. (2004), Nabekura et al. (2010) |
| MRP-1 (ABCC-1)  | Etoposide, teniposide, vincristine, vinblastine, doxorubicin, daunorubicin, epirubicin, idarubicin, topotecan, irinotecan, mitoxantrone, chlorambucil, methotrexate, melphalan | Curcuma longa               | 2   | Shukla et al. (2009) |
| MRP-2 (ABCC-2)  | SN-38G (metabolite of irinotecan), methotrexate, sulfipyrazzone, vinblastine | Inchin-ko-to                | 2   | Okada et al. (2007) |
| BCRP (ABCG-2, MXR) | 9-Aminocamptothecin, daunorubicin, epirubicin, etoposide, lurtotecan, mitoxantrone, SN-38, topotecan | Flavonoid-containing herbs such as Glycine max (soybean), Gymnema sylvestre, and Cimicifuga racemosa (black cohosh) | 2   | Merino et al. (2010), Tamaki et al. (2010) |

LE, level of evidence.

**ABC, ATP-binding cassette; BCRP, breast cancer resistance protein; MDR, multidrug resistance gene; MRP, multidrug resistance-associated protein; MXR, mitoxantrone resistance-associated protein.**
### Table 5 | Some herbal remedies capable of interacting with other drugs via alteration in renal functions.

| Medicinal plants | Brief description | Mechanism | LE | Reference |
|------------------|-------------------|-----------|----|-----------|
| Aristolochia fangchi | Chinese slimming herbal remedy | Aristolochic acid content forms DNA adducts in renal tissues leading to extensive loss of cortical tubules | 4 | Lai et al. (2010) |
| Djenkol bean (Pithecellobium lobatum) | Pungent smelling edible fruit, used for medicinal purposes in Africa | Contains nephrotoxic djenkolic acid | 3 | Luyckx and Naicker (2008), Markell (2010) |
| Impila (Callilepis laureola) | Popular South African medicinal herb | Causes damage to the proximal convoluted tubules and the loop of henle, shown to be hepatotoxic | 3 | Steenkamp and Stewart (2005) |
| Wild mushrooms | Widely consumed in Africa | Some species especially *Cortinarius* contains nephrotoxic orellanine | 3 | Wolf-Hall (2010) |
| Licorice root (Glycyrrhiza glabra) | Leguminous herb native to Europe and Asia, root and extracts are used in chronic hepatitis and other ailments | Contains glycyrrhizic acid whose metabolite, glycyrrhetinic acid inhibits renal 11-hydroxysteroid dehydrogenase leading to a pseudoaldosterone-like effect – accumulation of cortisol in the kidney, stimulation of the aldosterone receptors in cells of the cortical leading to increased BP, sodium retention, and hypokalemia. This may potentiate the action of drugs such as digoxin | 4 | Isbrucker and Burdock (2006), Kataya et al. (2011) |
| Noni fruit (*Morinda citrifolia*), alfalfa (*Medicago sativa*), Dandelion (*Taraxacum officinale*), horsetail (*Equisetum arvense*), stinging nettle (*Urtica dioica*) | These plants and their extracts are used variously in traditional medicine, and have been shown to contain very high potassium levels | Hyperkalemic, hepatotoxic | 3 | Saxena and Panbutra (2003), Stadlbauer et al. (2005), Jha (2010) |
| Rhubarb (*Rheum officinale*) | Used as laxative | High oxalic acid content may precipitate renal stone formation and other renal disorders | 1 | Bihl and Meyers (2001) |
| Star fruit (*Averrhoa carambola*) | A tree popular in Southeast Asia and South America, employed traditionally as antioxidant and antimicrobial | Oxalate nephropathy | Chen et al. (2001), Wu et al. (2011) |
| *Uva ursi* (*Arctostaphylos uva ursi*), goldenrod (*Solidago virgaurea*), dandelion (*Taraxacum officinale*), juniper berry (*Juniperus communis*), horsetail (*Equisetum arvense*), lovage root (*Levisticum officinale*), parsley (*Petroselinum crispum*), asparagus root (*Asparagus officinalis*), stinging nettle leaf (*Urtica dioica*), alfalfa (*Medicago sativa*) | Various plants used as diuretics | Plants have diuretic property\(^1\) and may increase the renal elimination of other drugs | 1 | Dearing et al. (2001), Wojcikowski et al. (2009) |

**LE**, level of evidence.

\(^1\)Some of these herbs exert their diuretic effects via extra-renal mechanisms with no direct effects on the kidneys (see Dearing et al., 2001).

---

Izzo et al. (1997) demonstrated that anthranoids could be harmful to the gut epithelium by inhibiting Na\(^{+}/K\(^{+}\)\) ATPase and increasing the activity of nitric oxide synthase. This significantly increased intestinal transit due to the alteration in the intestinal water and salt absorption and the subsequent fluid accumulation. In a study conducted by Munday and Munday (1999), a garlic-derived compound was shown to increase the tissue activities of quinone reductase and glutathione transferase in the gastrointestinal tract of the rat. In view of their roles in metabolism, both enzymes are considered chemoprotective especially from chemical carcinogens. In addition to CYP and P-gp mediated mechanisms, the well-known ginseng-induced pharmacokinetic HDI may also be due to its gastrointestinal effects especially its inhibitory effects on gastric secretion (Suzuki et al., 1991). The potential of rhein and...
| Medicinal plant                    | Major active ingredients                                                                 | Indications                      | Mechanism of action                                           | Drug candidates for potential interactions | LE | Reference                                      |
|----------------------------------|------------------------------------------------------------------------------------------|----------------------------------|----------------------------------------------------------------|--------------------------------------------|----|------------------------------------------------|
| Vaccinium macrocarpon            | Anthocyanins, flavonoids                                                                 | Antioxidant                      | VKORC1 * genotype dependent interaction                        | Warfarin                                   | 4  | Mohammed et al. (2008)                          |
| Ternstroemia pringlei            | Essential oils: monoterpenes                                                             | Sedative                         | Sedative synergy                                               | Sedatives, hypnotics                        | 2  | Balderas et al. (2008)                         |
| Aspilia africana                 | Alkaloids, tannins                                                                        | Malaria                          | Antagonism                                                     | Artemisinin, chloroquine                   | 1  | Waako et al. (2005), Abii and Onuoha (2011)   |
| Digitalis lanata (Grecian foxglove, wooly foxglove) | Acetyldigoxin, digitalin, digoxin, digitoxin, gitalin, lanatosides | Cardiotonic                      | Positive inotrope                                              | Cardiovascular drugs                        | 1  | Wood et al. (2003)                            |
| Anabasis sphylla                  | Anabasine                                                                                 | Skeletal muscle relaxant         | Nicotinic receptor agonist which at high doses produces a depolarizing block of nerve transmission | Muscle relaxants                            | 1  | Taylor (2000)                                 |
| Anisos tanguticus                | Anisodine, Anisodamine                                                                    | Used in treating acute circulatory shock in China | Anticholinergic                                             | Cholinomimetics                             | 1  | Fabricant and Famsworth (2001)                 |
| Adonis vernalis (pheasant’s eye, red chamomile) | Adoniside                                                                               | Cardiotonic                      | Cardiostimulant                                               | Cardiovascular drugs                        | 1  | Lange (2000)                                 |
| Areca catechu (Betel nut)         | Arecoline                                                                                 | Relaxing drug                    | Direct acting cholinergic agonist                              | Cholinergic agents, CNS drugs              | 4  | Boucher and Mannan (2002)                      |
| Peumus boldus (Boldo)            | Boldine                                                                                   | Indigestion, constipation, hepatic disorders laxative | Increasing GIT motility                                       | Orally administered drugs                  | 1  | De Almeida et al. (2000)                      |
| Rhamnus purshiana (Cascara)       | Anthracene glycosides                                                                     | RTI, chicken pox, TB, STI, pain, TB, weight loss | Estrogenic activity, hepatotoxicity                            | Steroids                                   | 3  | Arteaga et al. (2005)                         |
| Lamea tridentata (Chaparral)      | Lignans, flavonoids, volatile oils, amino acids                                         | Glycoproteins, polysaccharides, vitamin C | Energy replenishing agent, diabetes, liver, and kidney diseases | Hypoglycemic agents, immunosuppressants     | 3  | He and Liu (2005)                            |

(Continued)
| Medicinal plant                  | Major active ingredients                  | Indications                        | Mechanism of action                              | Drug candidates for potential interactions       | LE | Reference |
|---------------------------------|------------------------------------------|------------------------------------|--------------------------------------------------|--------------------------------------------------|----|-----------|
| *Salvia miltiorrhiza* (Danshen) | Tanshinones, phenolic compounds          | Cardiovascular diseases            | Vasorelaxants, antiplatelets                      | Warfarin, vasodilators, anticoagulants            | 3  | Shi et al. (2005), Wu and Yeung (2010) |
| *Angelica sinensis* (Dong quai) | Phytoestrogens, flavonoids, coumarins    | Gynecological and circulation disorders | Estrogenic, vasorelaxant, anti-inflammatory       | Contraceptives, vasodilators, anticoagulants, antiplatelets | 3  | Goh and Loh (2001), Ciricosta et al. (2006) |
| *Harpagophytum procumbens* (Devils claw) | Harpagophy cumbens | Musculoskeletal and arthritic pain | Anti-inflammatory, anti-arrhythmic, positive inotropic | Anti-arrhythmias                                 | 3  | Galindez et al. (2002) |
| *Echinacea species*             | Alkamides, phenols, polysaccharides      | Upper respiratory tract infections | Immunostimulants                                 | Immunosuppressants                               | 3  | Barnes et al. (2005) |
| *Trigonella foenum-graecum* (Fenugreek) | Alkaloids, flavonoids, saponins         | Diabetes, hypercholesterolemia     | Antilipidemic, hypoglycemic, cholagogue          | Oral hypoglycemic agents                         | 2  | Tripathi and Chandra (2010), Moorthy et al. (2010), Baquer et al. (2011) |
| *Tanacetum parthenium* (Feverfew) | Parthenolide, tanetin                   | Headache, fever, arthritis         | Inhibition of serotonin and prostaglandin release, thus altering platelet function | Antiplatelets, anticoagulants                    | 2  | Rogers et al. (2000) |
| *Allium sativum* (Garlic)       | Allins                                   | Hypercholesterolemia, prevention of arteriosclerosis | Antihypertensive, anti-diabetic, antiplatelet, antilipidemic | Propranolol, hypoglycemic agents, anticoagulants | 3  | Asdaq et al. (2009), Asdaq and Inamdar (2011) |
| *Zingiber officinale* (Ginger) | Zingerone, gingerols                    | Nausea, dyspepsia                  | Antiemetic, antiplatelet, antiulcer              | Diclofenac, anticoagulants                        | 3  | Lala et al. (2004), Young et al. (2006) |
| *Ginko biloba* (Ginko)          | Flavonoids, ginkgolides, ginkgolic acid | Cardioprotection, dementia, antioxidant | Alteration in platelet function                  | Anticoagulants, antiplatelets                     | 3  | Yagmur et al. (2005) |
| *Panax ginseng* (Ginseng)       | Triterpene saponins (ginsenosides)      | Loss of energy and memory, stress, male sexual dysfunction | Immunomodulatory, hypoglycemic | Immunosuppressants, hypoglycemic agents | 3  | Wilasrusmee et al. (2002), Ni et al. (2010) |
| *Chelidonium majus* (Greater celandine) | Alkaloids                               | Gallstones, dyspepsia              | Hepatotoxicity                                   | Liver-dependent metabolism                       | 3  | Crins et al. (2002), Gilca et al. (2010) |
| *Camellia sinensis* (Green tea) | Polyphenols, caffeine                   | Cardiovascular diseases, prevention of cancer | Antioxidants, CNS stimulants, antilipidemic       | Sedatives, hypnotics, and anxiolytics             | 1  | Ferrara et al. (2001) |
| Plant Name                                    | Main Constituents                            | Medical Conditions                                      | Interactions                                      | Reference               |
|-----------------------------------------------|----------------------------------------------|---------------------------------------------------------|---------------------------------------------------|-------------------------|
| *Cyamopsis tetragonolobus* (Guar gum)         | Galactomannan, lipids, saponin               | Diabetes, obesity, hypercholesterolemia                 | Hypoglycemic, antilipidemic                        | 2 Mukhtar et al. (2006) |
| *Callilepis laureola* (Impila)                | Atractyloside                                | GIT disorders, fertility, cough, worm infestations      | Hepatotoxicity                                    | 3 Stewart et al. (2002) |
| *Lycoodium serratum* (Jin Bu huan)            | Tetrahydropalmatine                          | Sedative, analgesic                                     | Hepatotoxicity                                    | 3 Emma (2008)           |
| *Piper methysticum* (Kava)                    | Kavapyrones                                  | Anxiety, insomnia                                       | Anxiolytic, anesthetic, muscle relaxants          | 2 Feltenstein et al. (2003) |
| *Catha edulis* (Khat)                         | Cathinone                                    | Loss of energy                                          | CNS stimulant, indirect sympathomimetic           | 1 Al-Habori (2005)      |
| *Glycyrrhiza glabra* (Liquorice)              | Glycyrrhizinic acid                          | Gastric ulcer, catarrhs, inflammation                  | Antulcer, aldosterone-like effects (mineralocorticoid actions) expectorant, anti-inflammatory | 3 Armanini et al. (2002) |
| *Ephedra species* (Ma-huang)                  | Ephedrine                                    | Weight loss                                             | Hepatotoxicity                                    | 3 Shekelle et al. (2003) |
| *Carica papaya* (Papaya)                      | Papain                                       | GIT disorders                                           | Alteration in platelet functions                  | 2 Ono et al. (2000)     |
| *Mentha pulegium* (Pennyroyal)                | Pulgenone                                    | Abortifacient, herbal tonic                             | Hepatotoxicity                                    | 2 Sztajnkrycer et al. (2008) |
| *Heliotropium species, senecio species, symphytum crotalaria* (Pyrrolizidines) | Pyrrolizidine alkaloids                      | Herbal teas and enemas                                  | Hepatotoxicity                                    | 2 Huxtable and Cooper (2000) |
| *Eleutherococcus senticosus* (Siberian ginseng) | Eleutherosides                               | Loss of energy and memory, stress, male sexual dysfunction | Immunomodulatory, anti-inflammatory, antitumor    | 4 Szolomicki et al. (2000) |
| *Glycine max* (Soya)                          | Phytoestrogens                               | Menopausal symptoms, prevention of heart diseases and cancer | Hepatoprotective, anti-osteoporosis               | 4 Albert et al. (2002)  |

(Continued)
| Medicinal plant                          | Major active ingredients                      | Indications                  | Mechanism of action                          | Drug candidates for potential interactions | LE | Reference                                |
|----------------------------------------|-----------------------------------------------|------------------------------|----------------------------------------------|---------------------------------------------|----|------------------------------------------|
| Tamarindus indica (Tamarind)           | Saponins, flavonoids, sesquiterpenes, tannins | Stomach disorder, jaundice  | Alteration in platelet functions             | Anticoagulants                              | 3  | Scott et al. (2005)                        |
| Atropa belladonna (Deadly nightshade)  | Atropine                                      | Motion sickness, GIT         | Anticholinergic                              | Cholinergic drugs                           | 1  | Ulbricht et al. (2008)                    |
| Camellia sinensis, Theobroma cacao, Thea species | Caffeine                                      | CNS stimulant                | CNS stimulant                                | CNS drugs                                   | 1  | Ashihara and Crozier (2001)               |
| Cissampelos pareira (Velvet)           | Cissampeline                                  | Skeletal muscle relaxant     | Muscle relaxants                             | Muscle relaxants                            | 2  | Bafna and Mishra (2010)                   |
| Convallaria majalis (Lily of the valley) | Convallatoxin                                | Cardiotoxic                  | Cardiostimulant                              | Cardiovascular drugs                        | 3  | Knight and Walter (2002)                  |
| Rauwolfia canescens; Rauwolfia serpentina | Deserpidine, reserpine                        | Antihypertensive, tranquilizer | Antihypertensive                            | Cardiovascular drugs                        | 3  | Emilio et al. (1998)                      |
| Octea glaziovii                        | Glasiovine                                    | Antidepressant               | Antidepressant                               | CNS drugs                                   | 3  | Maridass and De Britto (2008)             |
| Black henbane, stinking nightshade, henpin | Hyoscyamine                                  | GIT disorders                | Anticholinergic                              | Cholinergic drugs                           | 3  | Gilani et al. (2008)                      |
| Khetin                                 | Kheltin                                       | Asthma                       | Bronchodilator                               | Anti-asthma drugs                           | 1  | Ziment and Tashkin (2000)                 |
| Ouabain tree                           | Ouabain                                       | Cardiotoxic                  | Cardiostimulant                              | Cardiovascular drugs                        | 1  | Schoner (2000)                            |
| Calabar bean                           | Physostigmine                                 | Antihypertensive             | Cholinesterase inhibitor                     | Cholinergic drugs                           | 3  | Hsieh et al. (2008)                       |
| Jaborandi, Indian hemp                 | Pilocarpine                                   | Purgative                    | Parasympathomimetic                          | Cholinergic drugs                           | 3  | Agra et al. (2007)                        |
| White false hellebore                  | Protoveratrineines A, B                       | Antihypertensives            | Antihypertensive                             | Cardiovascular drugs                        | 3  | Gaillard and Pepin (2001)                 |
| squill                                 | Scillarin A                                   | Cardiotoxic                  | Sedative                                    | Sedative                                    | 1  | Marx et al. (2005)                        |
| Jimsonweed                             | Scopolamine                                   | Sedative                     | Sedative                                    | Cardiovascular drugs                        | 2  | Ayuba and Ofojekwu (2005)                 |
| Yohimbe                                | Yohimbine                                     | Antihypertensive             | Antihypertensive effects                     | Cardiovascular drugs                        | 2  | Yao and Jiang (2002)                      |

*VKORC1, vitamin K epoxide reductase complex subunit 1.*

References:

- Scott et al. (2005)
- Ulbricht et al. (2008)
- Ashihara and Crozier (2001)
- Bafna and Mishra (2010)
- Knight and Walter (2002)
- Emilio et al. (1998)
- Maridass and De Britto (2008)
- Gilani et al. (2008)
- Ziment and Tashkin (2000)
- Schoner (2000)
- Hsieh et al. (2008)
- Agra et al. (2007)
- Gaillard and Pepin (2001)
- Marx et al. (2005)
- Ayuba and Ofojekwu (2005)
- Yao and Jiang (2002)
- Ajayi et al. (2003)
danthon to increase the absorption of furosemide, a poorly water-soluble drug, has been demonstrated through in vitro studies (Lahtinen et al., 2007). In a study carried out on mice, a Chinese herbal plant, Polygonum paleaceum, showed the potential to depress the motility of the gastrointestinal tract, inhibit defecation reflex and delay gastric emptying (Zhang, 2002). A similar study demonstrated the inhibitory effects of two Chinese traditional herbal prescriptions, Fructus aurantii immaturus and Radix paeoniae alba on gastrointestinal movement (Fang et al., 2009).

The absorption of drugs such as phenoxymethylpenicillin, metformin, glibenclamide, and lovastatin may be reduced by high-fiber herbal products through the sequestration of bile acids (Colalto, 2010). Mochiki et al. (2010) reported the ability of Kamplo, a traditional Japanese medicine, to stimulate elevated intestinal blood flow, and to induce increased secretion of gastrointestinal hormones including motilin, vasoactive intestinal peptide, and calcitonin gene-related peptide. Similarly, another traditional Japanese medicine has been shown to increase the intestinal secretion of ghrelin, a hunger-related hormone, leading to delayed gastric emptying (Tokita et al., 2007; Kawahara et al., 2009; Hattori, 2010; Matsumura et al., 2010). Also, Qi et al. (2007) demonstrated the capability of Da-Cheng-Qi-Tang, a traditional Chinese herbal formula, to increase plasma motilin, enhance gastrointestinal motility, improve gastric dysrhythmia, and reduce gastroparesis after abdominal surgery. These effects have the potential of reducing the intestinal transit time of concurrently administered drug, with the risk of reduced absorption.

**Alteration in renal elimination**

This involves herbal products capable of interacting with renal functions, leading to altered renal elimination of drugs. Such interaction can result from the inhibition of tubular secretion, tubular reabsorption, or interference with glomerular filtration (Isnard et al., 2004). In addition to this group of herbal products are those products consumed as diuretics. The mechanism of herbal diuresis is complex and non-uniform. Certain herbs increase the glomerular filtration rate but do not stimulate electrolyte secretion while some others act as direct tubular irritants (Crosby et al., 2001; Al-Ali et al., 2003). Some herbs capable of interacting with renal functions and drug elimination are presented in Table 5.

**Pharmacodynamic synergy, addition, and antagonism**

Herb–drug interaction can occur through the synergistic or additive actions of herbal products with conventional medications as a result of affinities for common receptor sites (Ma et al., 2009). This can precipitate pharmacodynamic toxicity or antagonistic effects (Table 6). Like most other herbs, SJW contains complex mixture of phytochemicals including phenylpropanes, naphthodanthrones, acylphloroglucinols, flavonoids, flavanol glycosides, and biflavones. Hyperforin is known to inhibit the reuptake of neurotransmitters (dopamine, serotonin, noradrenaline) and is believed to be the bioactive responsible for the antidepressant activity of SJW.

**CONCLUSION**

Concomitant use of herbs and conventional drugs may present with untoward events. Evidence available in literature indicates various mechanisms through which this can occur. By interacting with conventional medication, herbal remedies may precipitate manifestations of toxicity or in the other extreme, therapeutic failure. A good knowledge of the potential of commonly consumed herbal medicines to interact with prescription medicines, irrespective of the nature of evidence available, will equip health professionals in their practice. Apart from those demonstrated in significant number of human subjects, not all reported HDIs are clinically significant. As such, more clinically relevant research in this area is necessary. This review provides information on commonly used herbs and their potentials for HDI within the levels of evidence currently available.

**ACKNOWLEDGMENTS**

The authors will like to acknowledge the support of HOPE Kapstadt-Stiftung (HOPE Cape Town) and the Stellenbosch University Rural Medical Education Partnership Initiative (SURMEPI) for providing funds for this study.

REFERENCES

Abi, T. A., and Onuoha, E. N. (2011). The chemical constituents of the leaf of Aspilia africana as a scientific backing to its tradomedical potentials. Agric. J. 6, 28–30.

Agra, M. E., De Freitas, P. F., and Barbosa-Filho, J. M. (2007). Synopsis of the plants known as medicinal and poisonous in Northeast Brazil. Rev. Bras. Farmacogn. 17, 114–140.

Agrosi, M., Mischatti, S., Harrasser, P. C., and Savio, D. (2000). Oral bioavailability of active principles from herbal products in humans: a study on Hypericum perforatum extracts using the soft gelatin capsule technology. Phytomedicine 7, 455–462.

Ajayi, A. A., Newaz, M., Hercule, H., Saleh, M., Bode, C. O., and Oyekan, A. O. (2003). Endothelin-like action of Pausinystalia yohimbe aqueous extract on vascular and renal regional hemodynamics in Sprague Dawley rats. Methods Find. Exp. Clin. Pharmacol. 25, 817–822.

Al-Ali, M., Wahbi, S., Twaij, H., and Al-Badr, A. (2003). Tribulus terrestris: preliminary study of its diuretic and contractile effects and comparison with Zea mays. J. Ethnopharmacol. 85, 257–260.

Albert, A., Albare, C., Baré, F., Buendia, E., Cabero, A., Can explaining, M. J., Castelo-Branco, C., Chantre, P., Duran, M., Haya, J., Imbert, P., Julia, D., Lanchares, J. L., Llanza, P., Manubens, M., Miñano, A., Quereda, E., Ribes, C., and Vázquez, F. (2002). Efficacy and safety of a phytoestrogen preparation derived from Glicynex max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine 9, 85–92.

Al-Dheib, I. D., Arafa, T. A., and Irshaid, Y. M. (2010). The effect of Licorice drink on the systemic exposure of Verapamil in rabbits. Drug Metab. Lett. 4, 173–179.

Al-Habori, M. (2005). The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin. Drug Saf. 4, 1145–1154.

Alkharafi, K. M., and Frye, R. F. (2007). Effect of valerian, valerian/hops extracts, and valerenic acid on glucoeuronidation in vitro. Xenobiotica 37, 113–123.

Alvarez, A. L., Real, R., Perez, M., Mendezo, G., Prieto, J. G., and Merino, G. (2010). Modulation of the activity of ABC transporters (P-glycoprotein, MRPs, BCRP) by flavonoids and drug response. J. Pharm. Sci. 99, 598–617.

Amacher, D. E. (2010). The effects of cytochrome P450 induction by xenobiotics on endobiotic metabolism in pre-clinical safety studies. Toxicol. Mech. Methods 20, 159–166.

Armanini, D., Fiore, C., Mattarello, M. J., Bielenberg, J., and Palermo, M. (2002). History of the endocrine effects of Licorice. Exp. Clin. Endocrinol. Diabetes 110, 237–261.

Arteaga, I., Andrade-Cetto, A., and Caraballo, J. L., Andrade-Cetto, A., and Caraballo, J. L., and Cárdenas, R. (2005). Larrea tridentata (Cresote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J. Ethnopharmacol. 98, 231–239.
Ayuba, V. O., and Inamdar, M. N. (2011). Pharmacodynamic and pharmacokinetic interactions of prapranolol with garlic (Allium sativum) in rats. Evid. Based Complement. Alternat. Med. 2011, 824042.

Asdaq, S. M., and Inamdar, M. N. (2011). Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharm. Res. 62, 207–227.

Coppola, M., and Mondola, R. (2012). Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review. Nord. J. Psychiatry 66, 73–78.

Cordia, W., and Steenkamp, V. (2011). Drug interactions in African herbal remedies. Drug Metabol. Drug Interact. 26, 53–63.

Cox, M. C., Low, J., Lee, J., Walseh, J., Demitra, N., Berman, A., Pereme- nter, M. G., Petrov, W. P., Price, D. K., Figg, W. D., Sparreboom, A., and Swain, S. M. (2006). Influence of gar- lic (Allium sativum) on the pharmacokinetics of doxorubicin. J. Natl. Cancer Inst. 98, 203–209.

Fasini et al. Herb–drug interactions

Frontiers in Pharmacology | Pharmaceutical Medicine and Outcomes Research April 2012 | Volume 3 | Article 69 | 14

Asdaq, S. M., and Inamdar, M. N. (2010). Pharmacodynamic inter- action of captopril with garlic in isoproterenol-induced myocardial damage in rat. Phytother. Res. 24, 720–725.

Barnes, J., Anderson, L. A., Gibbons, S., and Philippson, J. D. (2005). Echi- nacea species (Echinacea angustifo- lia (DC.) H. Echinacea purpurea (L. Moench: a review of their chemistry, pharmacology and clin- ical properties. J. Pharm. Pharmacol. 57, 929–954.

Behbouy, M., and See, D. M. (2008). Target- ing P-glycoprotein for effective oral anti-cancer chemotherapeutics. Curr. Cancer Drug Targets 8, 47–52.

Bensouass, A., Myers, S. P., Wu, S. M., O’Connor, K. (2004). Naturopathic and Western herbal medicine prac- tice in Australia – a workforce survey. Complement. Ther. Med. 12, 17–27.

Berginc, K., and Kristl, A. (2012). The effect of garlic supplements and phy- tochemicals on the ADMET prop- erties of drugs. Expert Opin. Drug Metab. Toxicol. 8, 295–310.

Bihl, G., and Meyers, A. (2001). Recur- rent renal stone disease – advances in pathogenesis and clinical manage- ment. Lancet 358, 651–656.

Bilgi, N., Bell, K., Ananthakrishnan, A., Bihl, G., and Meyers, A. (2001). Recur- rent renal stone disease – advances in pathogenesis and clinical manage- ment. Lancet 358, 651–656.

Bodeker, G. (2007). T raditional health care and pharmaceuticals: a potential inter- action resulting in liver toxicity. Ann. Pharmacother. 44, 926–928.

Birnes, P., Coppin, D., Schmitt, L., and Laquc, D. (2003). Serotonin syn- drome: a brief review. CMAJ 168, 1439–1442.

Bonnet, N., Santelli, L., Battistini, L., and Cagnin, A. (2007). Serotonin syn- drome and rhabdomyolysis induced by concomitant use of triptans, Bu- curaine and hypericum. Cephalalgia 27, 1421–1423.

Borrel, M. N., Pereira, E., Fiallo, M., and Garnier-Suillerot, A. (1994). Acute oxalate nephropathy after ingestion of star fruit. Am. J. Kidney Dis. 37, 418–422.

Cheng, B., Hung, C. T., and Chiu, W. (2002). Herbal medicine and anae- thesia. Hong Kong Med. J. 8, 123–130.

Chitturi, S., and Farrell, G. C. (2000). Herbal hepatotoxicity: an expanding but poorly defined problem. J. Gastroenterol. Hepatol. 15, 1093–1099.

Chitturi, S., and Farrell, G. C. (2008). Hepatotoxic slimming aids and other herbal hepatotoxins. J. Gastroenterol. Hepatol. 23, 366–373.

Circosta, C., Pasquale, R. D., Palumbo, D. R., Samperi, S., and Ochi- uto, F. (2006). Estrogenic acitivity of standardized extract of Angelica sinensis. Phytother. Res. 20, 665–669.

Clement, Y. N., Williams, A. F., Khan, K., Bernard, T., Bhu, S., Fortuné, M., Medupe, O., Nagee, K., and Seaforth, C. E. (2005). A gap between acceptance and knowledge of herbal remedies by physicians: the need for educational intervention. BMC Complement. Altern. Med. 5, 20. doi:10.1186/1472-6882-5-20
De Maat, M. M., Hoetelmans, R. M. W., Mathôt, R. A., van Gorp, E. C., Meenhorst, P. L., Mulder, J. W., and Beijnen, J. H. (2001). Drug interactions between St John’s wort and nevirapine. AIDS 15, 420–421.

Dearing, D. M., Mangione, A. M., and Karasov, W. H. (2001). Plant secondary compounds as diuretics: a case report. Eur. J. Pharmacol. Ther. 20, 469–471.

Engelberg, D., McCutcheon, A., and Wiseman, S. (2001). A case of gingam-induced mania. J. Clin. Psychopharmacol. 21, 535–537.

Ernst, E. (2002). St John’s wort supplement endangers the success of organ transplantation. Arch. Surg. 137, 316–319.

Ernst, E. (2004). Are herbal medicines effective? Int. J. Clin. Pharmacol. Ther. 42, 157–159.

Ernst, E. (2005). The efficacy of herbal medicine – an overview. Fundam. Clin. Pharmacol. 19, 405–409.

Fabricant, D. S., and Farnsworth, N. R. (2001). The value of plants used in traditional medicine. J. Ethnopharmacol. 110, 334–342.

Deghengi, M. K., Xia, C. Q., Yang, J. I., and Kim, R. B. (2012). Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol. 52, 249–273.

DeLeve, L. D., Schulman, H. M., and MacDonald, G. B. (2002). Toxic injury to hepatic sinuoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin. Liver Dis. 22, 27–42.

Delgoda, R., and Westlake, A. C. G. (2004). Herbal interactions involving cytochrome P450 enzymes: a mini review. Toxicol. Rev. 23, 239–249.

Di, Y. M., Li, C. C., Xue, C. C., and Zhou, S. F. (2008). Clinical drugs that interact with St John’s wort and implication in drug development. Curr. Pharm. Des. 14, 1723–1742.

Dresser, G. K., Schwarz, U. I., Wilkinson, G. R., and Kim, R. B. (2007). Coordinated induction of both cytochrome P450sA3 and MDR1 by St John’s wort in healthy subjects. Clin. Pharmacol. Ther. 81, 599–606.

Durazo, F. A., Arriaga-Alba, M., Castañeda-Corral, G., Angeles-López, G. E., Navarrete, A., and Mata, R. (2007). Acute toxicity and mutagenic activity of Mexican plants used in traditional medicine. J. Ethnopharmacol. 110, 334–342.

Epstein, S. M., Liberman, N., Klang, S., and Kahan, E. (2004). Are people who use ‘natural drugs’ aware of their potentially harmful side effects and reporting to family physician? Patient Educ. Couns. 53, 5–11.

Goh, S. Y., and Loh, K. C. (2001). Gynaecomastia and the herbal tonic ‘dong quai.’ Singapore Med. J. 42, 115–116.

Gresson, J. M., Sanford, B., and Monti, D. A. (2001). St John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl.) 153, 402–414.

Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., and Ang, C. Y. (2005). Clinical assessment of botanical supplementation on cytochrome P450 phenotype in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22, 525–539.

Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Khan, I. A., and Shah, A. (2005b). In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1 and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 77, 415–426.

Hafner, V., Jäger, M., Mattheé, A. K., Ding, R., Burhenne, J., Haefeli, W. E., and Mikus, G. (2009). Effect of simultaneous induction and inhibition of CYP3A4 by St John’s wort and ritonavir on CYP3A activity. Clin. Pharmacol. Ther. 87, 191–196.

Hamann, G. L., Campbell, J. D., and George, C. M. (2011). Warfarin–cranberry juice interaction. Ann. Pharmacother. 45, 1417.

Hattori, T. (2010). Rikkunshito and ghrelin. Int. J. Pept. 2010, pi: 285549.

He, L., and Liu, P. (2005). Effect of Lycium barbarum polysacchrides on oxidative stress of diabetic nephropathy in type 2 diabetic rats. Chinese J. Hosp. Pharm. 12, 34–40.

He, S. M., Li, R., Kanwar, J. S., and Zhou, S. F. (2011). Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr. Med. Chem. 18, 439–481.

Henderson, L., Yue, Q. Y., Bergquist, C., Gerden, B., and Arlet, P. (2002). St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharmacol. 54, 349–356.

Herrmann, M. (2011). In vitro assessment of the allelic variants of cytochrome P450. Drug Metab. Pharmacokinet. [Epub online ahead of print].

Hojo, Y., Echizenya, M., Ohkubo, T., and Shimizu, T. (2011). Drug interaction between St John’s wort and zolpidem in healthy subjects. J. Clin. Pharm. Ther. 36, 711–715.

Hokkenj, J., Tolonen, A., Mattila, S., and Turpeinen, M. (2011). Metabolism of hyperforin, the active constituent of St John’s wort, in human liver microsomes. Eur. J. Pharm. Sci. 42, 273–284.

Homyo, J., King, R., Tenywa, J., Kyeiyune, P., Opio, A., Babala, D. (2004). Defining minimum standards of practice for incorporating African traditional medicine into HIV/AIDS prevention, care, and support: a regional initiative in eastern and southern Africa. J. Altern. Complement. Med. 10, 905–910.

Howell, L., Kochhar, K., Saywell, R. Jr., Zollinger, T., Koehler, J., Mandzuk, C., Sutton, B., Sevilla-Martir, J., and Allen, D. (2006). Use of herbal remedies by Hispanic patients: do they inform their physician? J. Am. Board Fam. Med. 19, 566–578.

Hayland, H. K. (2011). Use of Saint John’s wort against mild depression. Tidsskr. Nor. Lægeforen. 131, 837–839.

Hsieh, M. I., Yen, Z. S., Chen, S. C., and Fang, C. C. (2008). Acute cholelithic syndrome following ingestion of contaminated herbal extract. Emerg. Med. J. 25, 781–782.

Hu, Z., Yang, X., Ho, P. C., Chan, S. Y., Heng, P. W., Chan, E., Duan, W., Koh, H. L., and Zhou, S. (2005). Herbal drug interactions: a literature review. Drugs 65, 1239–1282.

Huang, Z., Xiao, B., Wang, X., Li, Y., and Deng, H. (2003). Betel nut...
indulgence as a cause of epilepsy. Seizure 12, 406–408.

Huatale, R. J., and Cooper, R. A. (2000). “Pyrrolizidine alkaloids: physicochemical correlates of metabolism and toxicity,” in Natural and Selected Synthetic Toxins, eds A. T. Tu and W. Gaffield (Washington: American Chemical Society), 100–117.

Iqbal, M., Sharma, S. D., Ozakazi, Y., Fujisawa, M., and Okada, S. (2003). Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in dY mice male: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol. Toxicol. 92, 33–38.

Ishucker, R. A., and Burdock, G. A. (2000). “Potential safety assessment on the consumption of Licorice root (Glycyrrhiza sp.), its extract and powder as a food ingredient, with emphasis on the pharmacology and toxicology of glycyrrhizin. Regul. Toxicol. Pharmacol. 26, 167–192.

Isnardi, B. C., Deray, G., Baumelou, A., Le Iwamoto, M., Kassahun, K., Troyer, M. (2009). Impact of rikkunshito, an herbal medicine, on human UGT1A1 activity. Drug Metab. Pharmacokinet. 24, 226–234.

Kaplan, D., D. Thomas, M. D., Hoffman, B., Horowitz, J. S., Kassaian, C., Kassaian, K. (2007). Decreased plasma levels of amitryptiline and its metabolites on comedication with an extract from St John's wort (Hypericum perforatum). J. Clin. Psychopharmacol. 22, 46–54.

Katah, H. Y., Amza, A., Ramadan, G. A., and Khassawneh, M. A. (2011). Effect of licorice extract on the complications of diabetes nephropathy in rats. Drug Chem. Toxicol. 34, 101–108.

Katoh, M., Yoshioka, Y., Nakagawa, N., and Yoko, T. (2009). Effects of Japanese herbal medicine, Kampo, on human UGT1A1 activity. Toxicol. Appl. Pharmacol. 232, 337–350.

Kepler, T. B., Doucette, W. R., and Horton, M. R. (2000). Assessment of patients’ perceptions and beliefs regarding herbal therapies. Pharmacotherapy 20, 83–87.

Knight, A. P., and Walter, R. G. (2002). “Plants affecting the cardiovascular system,” in A Guide to Plant Poisoning of Animals in the Americas, eds A. P. Knight and R. G. Walter. Available at: http://www.ivis.org/special_books/Knight/chap2/ivis.pdf [accessed November 05 2011].

Kristna, R., and Mayer, L. D. (2001). Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. Curr. Med. Chem. Anticancer Agents 1, 163–174.

Lai, M. N., Wang, S. M., Chen, P. C., Chen, Y. W., and Wang, J. D. (2010). Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J. Natl. Cancer Inst. 102, 179–186.

Laitinen, L., Takala, E., Vuorela, H., Vuorela, P., Kaukonen, A. M., and Marvola, M. (2007). Ananthanralaxative influence the absorption of poorly permeable drugs in human intestinal cell culture model (Caco-2). Eur. J. Pharm. Biopharm. 66, 135–145.

Lala, L. G., D’Mello, P. M., and Naik, S. R. (2004). Pharmacokinetic and pharmacodynamic studies on interaction of “Trikatu” with diclofenac sodium. J. Ethnopharmacol. 91, 277–280.

Lange, D. (2000). Conservation and Sustainable use of Adonis Vernalis, a Medicinal Plant in International Trade. Bonn: Federal Agency for Nature Conservation, 88.

Larsen, A. K., Escargueil, A. E., and Składanowski, A. (2000). Resistance mechanisms associated with altered intracellular distribution of anti-cancer agents. Pharmacol. Ther. 85, 717–229.

Lau, W. C., Welch, T. D., Shields, T., Rubenfire, M., Tantry, U. S., and Gurbel, P. A. (2011). The effect of St John’s wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J. Cardiovasc. Pharmacol. 57, 86–93.

Lawshe, S., and Mahoney, M. C. (2005). St John’s wort. Am. Fam. Physician 72, 2249–2254.

Leclercq, I., Farrell, G. C., Field, J., Bell, D. R., Gonzalez, F. J., and Robertson, G. R. (2000). CYP2E1 and CYP3A4 as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105, 1067–1075.

Lee, J. Y., Duke, R. K., Tran, V. H., Hook, J. M., and Duke, C. C. (2006). Hyperforin and its analogues inhibit CYP3A4 and P-glycoprotein. Phytomed. 13, 223–233.

Lewis, D. F. V. (2004). 57 varieties: the human cytochromes P450. Pharmaco- genomics 5, 305–318.

Lewis, J. H., Ahmed, M., Shobassy, A., and Palese, C. (2006). Drug-induced liver disease. Curr. Opin. Gastroenterol. 22, 223–233.

Li, M., Andrew, M. A., Wang, J., Salinger, D. H., Vicini, P., Grady, R. W., Phillips, B., Shen, D. D., and Anderson, G. D. (2009). Effects of cranberry juice on pharmacokinetics of beta-lactam antibiotics following oral administration. Antimicrob. Agents Chemother. 53, 2725–2732.

Li, Y., Xie, P., and Chen, K. (2004). Quality control of herbal medicines. J. Chromatogr. 812, 53–70.

Liao, H., Ma, T., Li, Y., Chen, J. T., and Chang, Y. S. (2010). Concurrent use of corticosteroids with Licorice-containing TCM preparations in Taiwan: a National Health Insurance Database Study. J. Altern. Complement. Med. 16, 539–544.

Liu, C. X., Yi, X. L., Si, D. Y., Xiao, X. F., He, X., and Li, Y. Z. (2011). Herb-drug interactions involving drug metabolizing enzymes and transporters. Curr. Drug Metab. 12, 835–849.

Luyckx, V. A., and Naicker, S. (2008). Acute kidney injury associated with the use of traditional medicines. Nat. Clin. Pruct. Nephrol. 4, 664–671.

Ma, X. H., Zheng, C. J., Han, L. Y., Xie, B., Jia, J., Cao, Z. W., Li, X. Y., and Chen, Y. Z. (2009). Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. Drug Discov. Today 14, 579–588.

Madabushi, R., Frank, B., Drewwel, B., Derendorf, H., and Butlerweck, V. (2006). Hyperforin in
Ono, S., Hatanaka, T., Hotta, H., Satoh, T., Gonzalez, F. J., Tsutsui, M. (1996). Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450 and human liver microsomes. Xenobiotica 26, 681–693.

Ozakir, A., Sadikoglu, G., Bayram, N., Mazicioglu, M. M., Bilgel, N., and Beyhan, I. (2007). Turkish general practitioners and complementary/alternative medicine. J. Altern. Complement. Med. 13, 1007–1010.

Paine, M. F., Widmer, W. W., Pusek, S. N., Beavers, K. L, Criss, A. B., Snyder, J., and Watkins, P. B. (2008). Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with chlorocruce. Am. J. Clin. Nutr. 87, 863–871.

Pal, D., and Mitra, A. K. (2006). MDR-and CYP3A4-mediated drug–herbal interactions. Life Sci. 78, 2311–2315.

Palombo, E. A. (2003). Phytochemicals from traditional medicinal plants used in the treatment of diarrhea: modes of action and effects on intestinal function. Phytother. Res. 20, 717–724.

Patanassethanont, D., Nagai, J., Yumoto, P., Patsalos, P., and Perucca, E. (2003). Clinical evaluation of in vitro metabolism using the N-in-one assay for cytochrome P450 enzymes. Biochem. Pharmacol. 75, 1426–1437.

Qiang, T., Latif, A., and Umegaki, K. (2012). Ginkgo biloba extract attenuates warfarin–oral anticoagulant interactions. Am. J. Health Syst. Pharm. 59, 339–347.

RCI, M., and Thiyagalingam, M. (2005). Simultaneous determination of ABCG2/BCRP1, a multi-drug-resistant and anti-inflammatory activities of the plant Andrographis paniculata Nees. Immunopharmacol. Immunotoxicol. 28, 129–140.

Roby, C. A., Anderson, G., Kantor, E., Roby, C. A., Anderson, G., Kantor, E., and Beyhan, I. (2007). Turkish gen- eral practitioners and complementary/alternative medicine. J. Altern. Complement. Med. 13, 1007–1010.

Salvador, T., Maria, V., and Jahangir, A. (2010). Herb–drug interactions with antiepileptic drugs and other drugs. Adv. Drug Res. 25, 159–164.

Sarris, J., LaPorte, E., and Schweitzer, K. (2011). Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust. N. Z. J. Psychiatry 45, 27–35.

Sawidou, S., Goulis, J., Giavazis, L., Patiasourea, K., Hytiroglou, P., and Arvanitakis, C. (2007). Herb–induced hepatitis by Teucrium polium L.: report of two cases and review of the literature. Eur. J. Gastroenterol. Hepatol. 19, 507–511.

Schena, A. K., and Panbotra, B. R. (2003). Herbal remedies: renal tragedies. Swiss Med. Wkly. 133, 188–189.

Schoner, W. (2000). Ouabain, a new steroid hormone of adrenal gland and hypophalamus. Exp. Clin. Endocrinol. Diabetes. 108, 449–454.

Scott, G. N., and Elmer, G. W. (2002). Update on natural product – drug interactions. Am. J. Health Syst. Pharm. 59, 339–347.

Smith, M., Dinehart, S. M., and Henry, L. (2000). Herbal hepatotoxicity. Semin. Liver Dis. 22, 195–206.

Steenkamp, V., and Stewart, M. (2005). Nephrotoxicity associated with exposure to plant toxins, with particular reference to Africa. Ther. Drug Monit. 27, 270–277.

Stewart, M. J., Steenkamp, V., van der Merwe, S., Zackernman, M., and Crowther, N. J. (2002). The cyto- toxic effects of a traditional Zulu remedy, irimpla (Callilepis laureola). Hum. Exp. Toxicol. 21, 643–647.

Suzuki, Y., Ito, Y., Konno, C., and Furuya, T. (1991). Effects of tissue cultured ginseng on gastric secretion and pepsin activity. Yakugaku Zasshi 111, 770–774.

Szakács, G., Váradi, A., Özvegy-Laczka, C., and Sarkadi, B. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov. Today 13, 379–393.

Szolomicki, S., Samochowiec, L., Wójcicki, J., and Drozdzik, M. (2000). The influence of active components of Eleutherococcus senticosus on cellular defence and physical fitness in man. Phytother. Res. 14, 30–35.

Tabish, Y. S., Ghanem, A. H., and Elsheikh, A. (2002). Herb–drug interactions with antiepileptic drugs and other drugs. Adv. Drug Res. 25, 159–164.

Takeda, H., and van den Berg, M. (2004). Herbal remedies: renal tragedies. Swiss Med. Wkly. 133, 188–189.

Tamine, N., Beavers, K. L, Criss, A. B., Snyder, J., and Watkins, P. B. (2008). Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with chlorocruce. Am. J. Clin. Nutr. 87, 863–871.

Tachjian, A., Maria, V., and Jahangir, A. (2010). Use of herbal products and potential interactions in patients with cardiovascular diseases. J. Am. Coll. Cardiol. 9, 513–523.

Taki, Y., Yokotani, K., Yamada, S., Shi-nozuka, K., Kabota, Y., Watanabe, Y., and Umegaki, K. (2012). Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 research. Drug Discov. Today 16, 793–799.

Thomson, N., Sas, A., Pascoa, H., Conceição, E. C., Alves, S. F., Diniz, D. G. A., Paula, J. R., and Bara, M. T. E. (2011). Dissolu- tion test of herbal medicines containing Paullinia cupana: validation of methods for quantification and assessment of dissolution. Braz. J. Pharm. Sci. 47, 269–277.

Spinella, M., and Eaton, L. A. (2002). Hypromania induced by herbal and pharmaceutical psychotropic medi- cines following mild traumatic brain injury. Brain Inf. 16, 359–367.

Stadlbauer, V., Fickert, P., Lackner, C., Schmerlaib, I., Krisper, P., Trauner, M., and Stauber, R. E. (2005). Hepato- toxicity of NONI juice: report of two cases. World J. Gastroenterol. 11, 2758–2762.

Stedman, C. (2002). Herbal hepatotoxicity. Semin. Liver Dis. 22, 195–206.

Steenkamp, V., and Stewart, M. (2005). Nephrotoxicity associated with exposure to plant toxins, with particular reference to Africa. Ther. Drug Monit. 27, 270–277.

Stewart, M. J., Steenkamp, V., van der Merwe, S., Zackernman, M., and Crowther, N. J. (2002). The cyto- toxic effects of a traditional Zulu remedy, irimpla (Callilepis laureola). Hum. Exp. Toxicol. 21, 643–647.

Suzuki, Y., Ito, Y., Konno, C., and Furuya, T. (1991). Effects of tissue cultured ginseng on gastric secretion and pepsin activity. Yakugaku Zasshi 111, 770–774.

Szakács, G., Váradi, A., Özvegy-Laczka, C., and Sarkadi, B. (2008). The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox). Drug Discov. Today 13, 379–393.

Szolomicki, S., Samochowiec, L., Wójcicki, J., and Drozdzik, M. (2000). The influence of active components of Eleutherococcus senticosus on cell- lular defence and physical fitness in man. Phytother. Res. 14, 30–35.

Sztajnjar, M. D., Otten, E. J., Bond, G. R., Lindell, C. J., and Goetz, R. J. (2008). Mitigation of penicillin oil hepatic toxicity in the mouse. Acad. Emerg. Med. 10, 1024–1028.

Tachjian, A., Maria, V., and Jahangir, A. (2010). Use of herbal products and potential interactions in patients with cardiovascular diseases. J. Am. Coll. Cardiol. 9, 513–523.

Taki, Y., Yokotani, K., Yamada, S., Shi-nozuka, K., Kabota, Y., Watanabe, Y., and Umegaki, K. (2012). Ginkgo biloba extract attenuates warfarin-mediated anticoagulation through induction of hepatic cytochrome P450 research. Drug Discov. Today 16, 793–799.
Umeshara, K. I., and Camesnisch, G. (2011). Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Pharm. Res. 29, 603–617.

Umezura, Y., Umeda, H., Yamamoto, T., and Ishii, T. (2009). Study on the pharmacokinetic-drug-drug interaction potential of Glycyrrhiza uralensis, a traditional Chinese medicine, with lidocaine in rats. Phytother. Res. 23, 603–607.

Tang, J., Li, Z., Zhang, J. N., Wu, Y. T., and Li, Z. X. (2006). Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother. Res. 20, 1046–1051.

Tannen, C., Engman, H., Knutson, L., Hedeland, M., Bondesson, U., and Lennermås, H. (2004). St John’s wort effects on human cytochrome P450 activity. Pharmacol. Ther. 36, 254–256.

Takikawa, T., Masui, M., and Hamazaki, K. (2004). Molecular modeling of cytochrome P450 and drug metabolism. Curr. Drug Metab. 11, 342–346.

Wang, J. F., and Chou, K. C. (2010). Anti-hyperglycemic and anti-hyperlipidemic effects of Daikenchuto, a traditional herbal medicine, with lido-

Wang, J. F., Shi, B., Cheng, Y., Xu, J., Jiang, M. I., Mikx, F., Burger, D. M., Koopmans, P. P., Verweij, P. E., Schoonen, W. G., and van der Ven, A. J. (2008). Evaluation of cytoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections. Basic Clin. Pharmacol. Toxicol. 102, 515–526.

Wang, R. O., H. N., Flikweert, S., le Van Roon, E. N., Flikweert, S., le Man, S., and Dvoricak, S. (2011). A combined in vitro and in vivo study of a potential drug–drug interaction caused by a structurally assessment approach. Drug Saf. 75, 298–309.

Taylor, L. (2000). Plants Based Drugs and Medicines. Available at: http://www. rain-tree.com/plantdrugs.htm [accessed November 03, 2011].

Tesche, R. (2010). Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 30, 1270–1279.

Tokita, Y., Yuzurihara, M., Sakaguchi, M., Satoh, K., and Kase, Y. (2007). The pharmacological effects of Daikenchuto, a traditional herbal medicine, on delayed gastrointestinal transit in rat postoperative ileus. J. Pharmacol. Sci. 104, 303–310.

Tripathi, U. N., and Chandra, D. (2010). Anti-hyperglycemic and anti-oxidative effect of aqueous extract of Morinda citrifolia pulp and Trigemina flavon rich gmo seed in alloxan-induced diabetic rats. Indian J. Biochem. Biophys. 47, 227–233.

Ulbricht, C., Chao, W., Costa, D., Rusie-Seamon, E., Weissner, W., and Woods, J. (2008). Clinical evidence of herb-drug interactions: a system-

www.frontiersin.org

April 2012 | Volume 3 | Article 69 | 19

P450 enzymes by bilobalide in mice. Phytomedicine 19, 177–182.

Tam, S. W., Worcel, M., and Wyllie, M. (2001). Yohimbine–a clinical review. Pharmacol. Ther. 91, 215–243.

Tamaki, H., Satoh, H., Shoji, O., and Sawada, Y. (2010). Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab. Pharmacokinet. 25, 170–179.

Tang, J., Song, X., Zhu, M., and Zhang, J. (2009). The relationship of isoflavonoids. Pharmacol. Ther. 192–193.

Zhang, Z., and Wong, Y. N. (2005). Enzyme kinetics for clinically relevant CYP inhibition. Curr. Drug Metab. 6, 241–257.

Zhou, S., Lim, Y. M., and Chowbay, B. (2004). Herbal modulation of P-glycoprotein. Drug Metab. Rev. 36, 57–104.

Zhu, H., Sun, Y., Xun, H., Han, S., Piao, M. L., Murata, Y., and Tada, M. (2004). Resistance imparted by traditional Chinese medicines to the acute change in glutamic pyruvic transaminase, alkaline phosphatase and creatine kinase activities in rat blood caused by blood. Biosci. Biotechnol. Biochem. 68, 1160–1163.

Ziment, I., and Tashkin, D. P. (2000). Alternative medicine for allergy and asthma. J. Allergy Clin. Immunol. 106, 603–614.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 20 December 2011; accepted: 05 April 2012; published online: 30 April 2012.

Citation: Fasinu PS, Bouic PJ and Rosenkranz B (2012) An overview of the evidence and mechanisms of herb-drug interactions. Front. Pharmacol. 3:90. doi: 10.3389/fphar.2012.00069

This article was submitted to Frontiers in Pharmacology, a specialty of Frontiers in Pharmacology.

Copyright © 2012 Fasinu, Bouic and Rosenkranz. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.